Tag: vrtx

Vertex Pharmaceuticals (VRTX) is rated HOLD as rich valuation leaves little margin for disappointment, even with strong free cash flow and a solid balance sheet. CF concentration remains the key risk, while new launches must keep scaling to justify the current multiple.

Read note